Organisers: the World Health Organization (WHO) and Medicines Patent Pool (MPP).
Date: 26th – 29th MAY 2026
Venue: PrideInn Azure Hotel Limited, Nairobi, Kenya
The Technical Training on Technology Transfer for IVD Manufacturers in Africa is a four-day, in-person training for manufacturers interested in entering technology transfer partnerships, as well as manufacturers already implementing technology transfer projects.
Recent stakeholder forums on diagnostics have focused on specific aspects of the technology value chains such as regulatory and market access enablers. However, consultations with manufacturers have highlighted the need for technical insight and tools to support the implementation of successful technology partnership. This includes but is not limited:
The purpose of the training is to equip IVD manufacturers in Africa with practical tools, frameworks, and real-world insights to make informed decisions about technology transfer agreement, and to successfully implement and complete technology transfer once it begins.
More details about the training are available here : Draft Concept Note and Agenda
Manufacturers interested in entering technology transfer partnerships and manufacturers that are already implementing technology transfer projects.
Specific objectives are to enable manufacturers to:
The training is designed to be highly interactive and grounded in real-world experience, the format will include:
By the end of the training, manufacturers are expected to:
Interested manufacturers are invited to register by completing the application form available, before 30th April 2026.
Senior Officers from the technical, quality, regulatory, and/or operational teams involved in IVD manufacturing.
—-
For further inquiries, please contact: technologytransfer@medicinespatentpool.org
This technical training is co-funded by The European Union and Unitaid. The content presented here is the sole responsibility of WHO and MPP and does not necessarily reflect the views of the donors.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.